Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03476369 · ClinicalTrials.gov registry record · Phase 4

Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention

A Phase 4 study, sponsored by The Guthrie Clinic.

Terminated
Registry status
Phase 4
Development phase
45
Enrollment target

NCT03476369 is a Phase 4 study that was terminated before completion, run by The Guthrie Clinic. The registered enrollment target is 45 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03476369, a Phase 4 study, was terminated before completion, sponsored by The Guthrie Clinic.

TERMINATED
Registry status
Phase 4
Development phase
45 participants
Enrollment target

Study Summary

During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study has demonstrated the decrease in effectiveness of Ticagrelor when administered along with Fentanyl. Hence this study was designed to further assess the interaction between crushed vs non crushed Ticagrelor and Fentanyl given during PCI procedures.

Interventions

  • DRUG Fentanyl
  • DRUG Ticagrelor 90Mg Tablet

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2018-04-18
Est. Completion 2025-01-23
Phase Phase 4

Sponsor

The Guthrie Clinic

17 total trials

What the Registry Record Tells You About NCT03476369

The ClinicalTrials.gov registry entry for NCT03476369 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Guthrie Clinic, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Fentanyl is the first listed.

NCT03476369 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03476369 about?

NCT03476369 is a clinical study titled "Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention". During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study has demonstrated the decrease in effectiveness of Ticagrelor when administered along with Fentanyl. Hence this study...

What is the current status of trial NCT03476369?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2018-04-18. Estimated completion is 2025-01-23.

What interventions are being tested in trial NCT03476369?

The interventions under investigation include: Fentanyl (DRUG), Ticagrelor 90Mg Tablet (DRUG).

Who is sponsoring clinical trial NCT03476369?

This trial is sponsored by The Guthrie Clinic, which has 17 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.